ESCC-话题@MedSci

#ESCC#

7篇内容 | 1300人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2205526, encodeId=4a0c22055261d, content=<a href='/topic/show?id=b860101129ac' target=_blank style='color:#2F92EE;'>#食管鳞状细胞癌#</a> <a href='/topic/show?id=d29fe127661' target=_blank style='color:#2F92EE;'>#癌前病变#</a> <a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=Nat Commu：刘芝华/陈洪岩/苏建忠开发用于早期检测食管鳞状细胞癌和癌前病变的新策略, objectType=article, longId=826515, objectId=5bcd826515c6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240519/1716097842254_5579292.png, objectUrl=/article/show_article.do?id=5bcd826515c6, replyNumber=0, likeNumber=77, createdTime=2024-05-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5bcd826515c6, moduleTitle=Nat Commu：刘芝华/陈洪岩/苏建忠开发用于早期检测食管鳞状细胞癌和癌前病变的新策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bcd826515c6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2183149, encodeId=e76621831490b, content=<a href='/topic/show?id=b860101129ac' target=_blank style='color:#2F92EE;'>#食管鳞状细胞癌#</a> <a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a> <a href='/topic/show?id=02bb11036040' target=_blank style='color:#2F92EE;'>#ASCO GI 2024#</a>, objectTitle=ASCO GI 2024：一线tiragolumab+阿替利珠单抗联合化疗治疗食管鳞状细胞癌（ESCC）患者的疗效（SKYSCRAPER-08研究）, objectType=article, longId=810442, objectId=d392810442ce, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240122/1705890201768_8624274.png, objectUrl=/article/show_article.do?id=d392810442ce, replyNumber=0, likeNumber=85, createdTime=2024-01-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d392810442ce, moduleTitle=ASCO GI 2024：一线tiragolumab+阿替利珠单抗联合化疗治疗食管鳞状细胞癌（ESCC）患者的疗效（SKYSCRAPER-08研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d392810442ce)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1581182, encodeId=1dfe158118267, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=J Clin Oncol：RATIONALE-302研究证实Tislelizumab ( 替雷利珠单抗)二线治疗可改善晚期或转移性食管鳞状细胞癌（ESCC）患者的OS, objectType=article, longId=727477, objectId=0a19e27477f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a19e27477f4, replyNumber=0, likeNumber=47, createdTime=2022-05-22, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a19e27477f4, moduleTitle=J Clin Oncol：RATIONALE-302研究证实Tislelizumab ( 替雷利珠单抗)二线治疗可改善晚期或转移性食管鳞状细胞癌（ESCC）患者的OS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a19e27477f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581181, encodeId=447b158118169, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=PeerJ：摄入油脂品种换一换，食管癌风险竟能差4倍？4个脂肪酸模式，1种可将ESCC风险翻一番，而另1种却打对折！, objectType=article, longId=723576, objectId=079de235769b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=079de235769b, replyNumber=0, likeNumber=83, createdTime=2022-04-07, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=079de235769b, moduleTitle=PeerJ：摄入油脂品种换一换，食管癌风险竟能差4倍？4个脂肪酸模式，1种可将ESCC风险翻一番，而另1种却打对折！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=079de235769b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581180, encodeId=d987158118097, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, objectType=article, longId=301417, objectId=e1c330141efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1c330141efe, replyNumber=0, likeNumber=57, createdTime=2022-03-24, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1c330141efe, moduleTitle=Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1c330141efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581179, encodeId=8c5f15811e92c, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, objectType=article, longId=300448, objectId=e70c30044809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e70c30044809, replyNumber=0, likeNumber=132, createdTime=2022-03-12, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e70c30044809, moduleTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e70c30044809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581178, encodeId=fd0515811e8b5, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, objectType=article, longId=295185, objectId=293529518574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=293529518574, replyNumber=0, likeNumber=58, createdTime=2022-02-07, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=293529518574, moduleTitle=Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=293529518574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581177, encodeId=14d215811e732, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, objectType=article, longId=221107, objectId=ae7022110e3c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae7022110e3c, replyNumber=0, likeNumber=52, createdTime=2021-11-28, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae7022110e3c, moduleTitle=Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae7022110e3c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1581176, encodeId=9ccf15811e66c, content=<a href='/topic/show?id=8a52699e7e' target=_blank style='color:#2F92EE;'>#ESCC#</a>, objectTitle=Gastroenterology：SLC39A6基因上调有助于食管鳞状细胞癌(ESCC)的诊断, objectType=article, longId=101131, objectId=f02010113143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f02010113143, replyNumber=0, likeNumber=64, createdTime=2017-06-09, rootId=0, userName=12498b08m95暂无昵称, userId=53e616746050, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f02010113143, moduleTitle=Gastroenterology：SLC39A6基因上调有助于食管鳞状细胞癌(ESCC)的诊断, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f02010113143)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESCC

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#食管鳞状细胞癌# #癌前病变# #ESCC#

Nat Commu：刘芝华/陈洪岩/苏建忠开发用于早期检测食管鳞状细胞癌和癌前病变的新策略

2024-05-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#食管鳞状细胞癌# #ESCC# #ASCO GI 2024#

ASCO GI 2024：一线tiragolumab+阿替利珠单抗联合化疗治疗食管鳞状细胞癌（ESCC）患者的疗效（SKYSCRAPER-08研究）

2024-01-22发表于上海

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

J Clin Oncol：RATIONALE-302研究证实Tislelizumab ( 替雷利珠单抗)二线治疗可改善晚期或转移性食管鳞状细胞癌（ESCC）患者的OS

2022-05-22

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

PeerJ：摄入油脂品种换一换，食管癌风险竟能差4倍？4个脂肪酸模式，1种可将ESCC风险翻一番，而另1种却打对折！

2022-04-07

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

Clin Cancer Res：ATTRACTION-3研究3年随访生存结果表明nivolumab较化疗改善晚期食管鳞状细胞癌（ESCC）患者预后

2022-03-24

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适

2022-03-12

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

Thorac Cancer：局部晚期可切除食管鳞状细胞癌(ESCC)使用脂质体紫杉醇+铂类方案作为新辅助化疗的疗效和安全性

2022-02-07

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

Front Oncol：SMART+顺铂（CDDP）/S1治疗老年食管鳞状细胞癌（ESCC）患者的疗效和安全性

2021-11-28

12498b08m95暂无昵称 (审核中...)

前往app查看评论内容

#ESCC#

Gastroenterology：SLC39A6基因上调有助于食管鳞状细胞癌(ESCC)的诊断

2017-06-09

科室
- - 订阅+
  - 更多科室
工具
服务